Prosecution Insights
Last updated: November 04, 2026
Application No. 17/903,768

BYPASS SYRINGE

Final Rejection §103
Filed
Sep 06, 2022
Priority
Sep 03, 2021 — provisional 63/240,413
Examiner
LAUER, CHRISTINA C
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Biolife Delaware L L C
OA Round
4 (Final)
69%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
472 granted / 688 resolved
-1.4% vs TC avg
Moderate +14% lift
Without
With
+14.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
42 currently pending
Career history
743
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
54.9%
+14.9% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
16.4%
-23.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 688 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments with respect to claim(s) 1 have been considered but are moot because the new ground of rejection over Kalb et al. US 20190315028 in view of Castelli US 2020/0289129 and further in view of Chong et al. US 2008/0269687. Applicant argues the amendment "the fluid bypass channel beginning at a first opening at a first position on the syringe barrel and ending at a second opening at a second position on the syringe barrel,...the syringe plunger seal may be positioned between the first position and the second position so that fluid may flow through the syringe nozzle into the syringe barrel and around the syringe plunger seal to an area behind the syringe plunger seal and out of an open end of the syringe barrel...." is not taught or disclosed by the cited references. Applicant argues that Chong discloses a substantially airtight seal around the plunger arm and a valve to allow for a vacuum to be applied to the chamber, the air tight seal would not allow for fluid to flow out of the end of the chamber. However, Kalb et al. discloses the device essentially as claimed including a syringe plunger shaft and a bypass channel on the syringe barrel (see annotated figure 4 below). The syringe plunger having an open end of the syringe barrel (to receive the plunger shaft and seal, figure 4) as amended. Examiner agrees Kalb et al. fails to disclose the fluid bypass channel beginning at a first opening at a first position on the syringe barrel and ending at a second opening at a second position on the syringe. However, this bypass channel structure is taught by Chong et al. (figure 88). Examiner notes the modification of Kalb et al. in view of Chong et al. is only for the structure of the bypass channel to include a first and second opening, and does not require the particulars of the rest of the claim language, such as an open end of the syringe barrel. Even so, it is to be noted Chong et al. discloses a seal 4474 along the proximal end of the syringe body, but also discloses a valve 4476 (figure 88) for applying a vacuum within chamber 4484 when the valve is open. When the valve is open, it would also be configured for fluid to flow out of the end of the chamber as claimed. Therefore, the amendment fails to overcome the prior art of record. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 3 and 4 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kalb et al. US 20190315028 in view of Castelli US 2020/0289129 and further in view of Chong et al. US 2008/0269687. Regarding claims 1, 3 and 4, Kalb et al. discloses an inflation device comprising a syringe barrel 8, a syringe plunger shaft (see annotated figure 4 below), a syringe nozzle 14 in fluid communication with the syringe barrel (figure 4, paragraph 0032, material inserted into device barrel and discharged through nozzle), and a syringe plunger seal 12, wherein the syringe barrel comprises a fluid bypass channel 2 extending laterally from the syringe barrel (figure 4), the fluid bypass channel beginning at a first position on the syringe barrel and ending at a second position on the syringe barrel (see annotated figure 4 below), wherein the distance between the first position and the second position is greater than the width of the syringe plunger seal such that when syringe plunger shaft is pushed toward the syringe nozzle (figure 4, forming a bypass channel, fluid configured to bypass because channel distance 4 is greater than plunger), the syringe plunger seal may be positioned between the first position and the second position so that fluid may flow through the syringe nozzle into the syringe barrel and around the syringe plunger seal to an area behind the syringe plunger seal (figure 4, forming a bypass channel, bypass channel by definition provides a secondary channel for fluid to flow around the plunger seal, shown in figure 4, the plunger 12 fits within the first and second position) and out of an open end of the syringe barrel (proximal end of syringe barrel is open to receive the plunger shaft and seal or tool 22 during formation, figures 3, 4), the bypass channel formed integrally with the syringe barrel (figure 3, formed with die part 21). Further, in accordance to MPEP 2113, the method of forming the device is not germane to the issue of patentability of the device itself. Therefore, this limitation has not been given patentable weight. Please note that even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product, i.e -the bypass channel being formed integrally with the syringe, does not depend on its method of production, i.e. ----. In re Thorpe, 227 USPQ 964, 966 (Federal Circuit 1985). PNG media_image1.png 290 635 media_image1.png Greyscale Kalb et al. fails to disclose the fluid bypass channel beginning at a first opening at the first position and ending at a second opening at the second position on the syringe barrel, wherein the first opening is located at a position on the syringe barrel beginning at a point corresponding to 10 to 65% of the total volume of the syringe barrel and the second opening is located at a position on the syringe barrel at a point corresponding to 25 to 80% of the total volume of the syringe barrel. PNG media_image2.png 496 772 media_image2.png Greyscale Chong et al. discloses an inflation device comprising a syringe barrel 4410 (see annotated figure 88 below), a syringe plunger shaft 4430 (see annotated figure 88 below), a syringe nozzle (see annotated figure 88 below), and a syringe plunger seal 4420 (see annotated figure 88 below) wherein the syringe barrel comprises a fluid bypass channel 4454 beginning at a first position on the syringe barrel and ending at a second position on the syringe barrel wherein the distance between the first position and the second position is greater than the width of the syringe plunger seal such that when syringe plunger shaft is pushed toward the syringe nozzle (see annotated figure 88 below), the syringe plunger seal may be positioned between the first position and the second position so that fluid may flow around the syringe plunger seal to an area behind the syringe plunger seal (flow into area 4484), wherein the syringe barrel comprises a bypass channel connected to the syringe barrel at two channel openings (channel 4454, figure 88; two openings at the first and second position), wherein the bypass channel is formed integrally with the syringe (channel 4454 is integral with the syringe). Chong et al. discloses wherein the first opening is located at a position on the syringe barrel and at a first point and the second opening is located at a position on the syringe barrel at a second point of the syringe barrel. Chong et al. fails to explicitly disclose wherein the first opening is located at a position on the syringe barrel and at a point corresponding to 10 to 65% of the total volume of the syringe barrel and the second opening is located at a position on the syringe barrel at a point corresponding to 25 to 80% of the total volume of the syringe barrel. However, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to cause the device of Chong et al. to have a first opening corresponding to 10 to 65% and a second opening corresponding to 25 to 80% of the syringe since it has been held that “where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device” Gardner v. TEC Syst., Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984), cert. denied, 469 U.S. 830, 225 SPQ 232 (1984). In the instant case, the device of Chong et al. would not operate differently with the claimed opening dimension configuration, as the openings are intended to function successfully with the claimed range, as shown in figure 88. Furthermore, applicant places no criticality on the range claimed, indicating that the openings could be located on that syringe location, only assuming the average syringe has a plunger of a particular length (paragraph 0043). Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify Chong et al. with a c bypass channel connected to the syringe barrel at two channel openings, as taught by Chong et al., and known in the art for providing a simple substation of one known element for another to obtain predictable results, such as providing a bypass channel on a syringe. Further, in accordance to MPEP 2113, the method of forming the device is not germane to the issue of patentability of the device itself. Therefore, this limitation has not been given patentable weight. Please note that even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product, i.e -the continuous bypass channel being formed integrally with the syringe, does not depend on its method of production, i.e. ----. In re Thorpe, 227 USPQ 964, 966 (Federal Circuit 1985). Kalb et al. fails to disclose a balloon in fluid communication with the syringe nozzle, wherein when the syringe plunger seal is positioned between the first and second position, the balloon relaxes based on an external pressure applied to the balloon. Castelli discloses a similar system comprising an inflation device comprising an expandable member or balloon (paragraph 0047) connected to one or more inflation devices such as a pump or a syringe to controllably inflate or deflate the balloon (paragraph 0070-72) and provide a tissue compression device configured to be inflated by a syringe and engage the and apply pressure to selected tissue (paragraph 0052). Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify Kalb et al. to be connected to an expandable member or balloon, as taught by Castelli, for applying a variable amount of pressure to the selected tissue. Examiner further notes that the balloon relaxes based on an external pressure applied to the balloon is functional language and the device in combination with the syringe of Kalb et al. being connected with the balloon of Castelli, form the same structure as claimed. Although not explicitly disclosed, when the syringe plunger seal is positioned between the first and second position and applying pressure to the balloon from an external force, the balloon would be configured to relax with an external force, as the air would flow through the bypass channel in the same manner. Claim(s) 5-8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kalb et al. US 20190315028 in view of Castelli US 2020/0289129 in view of Chong et al. US 2008/0269687, and further in view of Sudo US 5637100. Regarding claims 5-8, Kalb et al.in combination discloses a syringe having a bypass channel, but fails to disclose multiple bypass channels or multiple continuous bypass channels, wherein none of the multiple bypass channels is in fluid contact with another of the multiple bypass channels, or wherein at least one of the multiple bypass channels is in fluid contact with another of the multiple bypass channels However, Sudo teaches an inflation device comprising multiple bypass channels or multiple continuous bypass channels (syringe body may comprise one or more bypasses, bypass 11, bypass 14; figure 10, 12, column 3, lines 39-43), wherein none of the multiple bypass channels is in fluid contact with another of the multiple bypass channels (figure 12, first bypass 11 is blocked from fluid contact from bypass 14 by sealing stoppers 8 and 10), wherein at least one of the multiple bypass channels is in fluid contact with another of the multiple bypass channels (figure 8, bypass channels 11 and 14 are in fluid communication as the fluid may flow around the first sealing member when placed within bypass 14). Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify Kalb et al. with multiple bypass channels, as taught by Sudo, as is known in the art to provide one or more bypass channels as required for a particular bypass syringe design for a particular use, since such a modification would have involved a mere change in the form or shape of a component. A change in form or shape is generally recognized as being within the level of ordinary skill in the art. In re Dailey, 149 USPQ 47 (CCPA 1976). Claim(s) 37 and 38 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kalb et al. US 20190315028 in view of Castelli US 2020/0289129 and in view of Chong et al. US 2008/0269687, and further in view of Okamura US 2018/0280008. Regarding claims 37 and 38, Kalb et al. in combination with Castelli discloses an inflation device wherein the syringe plunger seal is selectively moveable within the syringe barrel (plunger seal moves with plunger shaft to deliver fluid within the syringe through the nozzle, figure 4, paragraph 0032, material inserted into device barrel and discharged through nozzle) and configured to provide a plurality a plurality of pre-inflation positions with both the first position on the syringe barrel and the second position on the syringe barrel between the syringe plunger seal and the nozzle effective to form a closed system and create pressure when the plunger seal is depressed towards the nozzle to inflate the balloon (when plunger is positioned proximally, as shown in figure 4); a plurality of balloon relaxation position with the syringe plunger seal between the first position on the syringe barrel and the second position on the syringe barrel effective to allow fluid to flow through the fluid bypass channel around the syringe plunger seal and out of the syringe barrel effective to allow the balloon to partially deflate (when plunger seal 12 is positioned within the bypass channel 2, configured to allow a balloon to partially deflate); and a plurality of balloon inflation positions with the syringe plunger seal between (1) the nozzle and (2) the first position and the second position on the syringe barrel such that the syringe plunger seal prevents fluid communication between the balloon and the fluid bypass channel and fluid is injected into the balloon as the syringe plunger seal is depressed towards the nozzle (when plunger is fully depressed to the distal end adjacent the nozzle, material has been delivered through the nozzle, the bypass channel being fully proximal to the nozzle resulting in no communication). Examiner notes in combination as discussed above, Castelli discloses a similar system comprising an inflation device comprising an expandable member or balloon (paragraph 0047) connected to one or more inflation devices such as a syringe to controllably inflate or deflate the balloon (paragraph 0070-0072) and provide a tissue compression device configured to be inflated by a syringe and engage the and apply pressure to selected tissue (paragraph 0052). Kalb et al. in combination with Castelli fails to further disclose a check valve secured to the syringe nozzle, a tube secured to the check valve with the check valve between the tube and the syringe, wherein the check valve is configured to maintain balloon inflation when the syringe barrel is not in fluid communication with the balloon. Okamura teaches a similar system comprising an inflation device comprising a balloon-like member 160 and a syringe (not shown, paragraph 0068, figure 1), further comprising a check valve secured to the syringe nozzle (with connector 173, paragraphs 0066, 0068 and 0069) for inflating a balloon-like member 160 (paragraph 0062), a tube 171 (figure 1) secured to the check valve (check valve within portion 173, with the check valve between the tube and the syringe, paragraph 0066, figure 1), wherein the check valve is configured to maintain balloon inflation when the syringe barrel is not in fluid communication with the balloon (closed and syringe is removed from connector, paragraph 0069). Examiner notes that in combination with a system comprising a syringe, balloon, tube and check valve as taught by the prior art, it would result in the structure and be configured for the functional language including plurality of positions as claimed. Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify Kalb et al. with a check valve secured to the syringe nozzle, a tube secured to the check valve with the check valve between the tube and the syringe, and a balloon secured to and in fluid communication with the tube, as taught by Castelli and Okamura, as is known in the art to provide inflation devices as claimed in combination with a check valve for positioning an occlusion balloon for stopping blood flow or providing controlled pressure at a particular tissue site. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINA C LAUER whose telephone number is (571)270-5418. The examiner can normally be reached Monday-Thursday 7:00 AM-4:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at (571) 272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTINA C LAUER/Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Show 1 earlier event
Mar 11, 2025
Non-Final Rejection mailed — §103
Jun 11, 2025
Response Filed
Jun 23, 2025
Final Rejection mailed — §103
Nov 24, 2025
Request for Continued Examination
Dec 04, 2025
Response after Non-Final Action
Dec 17, 2025
Non-Final Rejection mailed — §103
Mar 17, 2026
Response Filed
Apr 29, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12708414
BONE PLATE HOLE CAPS, BONE PLATE SYSTEMS, AND METHODS USING SAME
4y 0m to grant Granted Aug 18, 2026
Patent 12708359
SUTURE ANCHORS WITH ONE-WAY LOCKING MECHANISMS
2y 6m to grant Granted Aug 18, 2026
Patent 12709020
SURGICAL SYSTEM WITH VARIABLE ENTRY GUIDE CONFIGURATIONS
2y 5m to grant Granted Aug 18, 2026
Patent 12702416
SYSTEMS AND METHODS FOR MICROVASCULAR ANASTOMOTIC COUPLER RING DELIVERY DEVICE
2y 6m to grant Granted Aug 11, 2026
Patent 12697132
DEVICE AND METHOD FOR SCAR SUBCISION
5y 6m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
69%
Grant Probability
83%
With Interview (+14.1%)
3y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 688 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month